LARONIDASE

LARONIDASE
(la-ron'i-dase)
Aldurazyme
Classifications: enzyme replacement therapy;
Therapeutic: enzyme replacement therapy

Prototype: Pancrelipase
Pregnancy Category: B

Availability

2.9 mg/5 mL injection

Action

Laronidase is a recombinant form of human alpha-L-iduronidase used for enzyme replacement therapy in individuals with mucopolysaccharidosis I (MPSI). This is an inherited lysosomal storage disease caused by deficiency of the enzyme alpha-L-iduronidase.

Therapeutic Effect

Replacement therapy for individuals lacking the enzyme alpha-L-iduronidase in mucopolysaccharidosis.

Uses

Treatment of Hurler and Hurler-Scheie forms of mucopolysaccharidosis I (MPS I); treatment of moderate to severe Scheie form of MPS I.

Contraindications

Hypersensitivity to laronidase; children <5 y.

Cautious Use

Renal or hepatic dysfunction; history of allergies, asthma; hypersensitivity to drugs, especially recombinant forms; pregnancy (category B), lactation.

Route & Dosage

Mucopolysaccharidosis
Adult/Child (>5 y): IV 0.58 mg/kg infused over 3–4 h once/wk

Administration

Intravenous
  • Pretreatment with antipyretics and/or antihistamines 60 min prior to infusion is recommended.

PREPARE: IV Infusion: Determine volume of infusion based on the patient's body weight (100 mL if ≤20 kg or 250 mL if >20 kg). Prepare IV infusion of 0.1% albumin (human) in NS injection as follows: 1) remove and discard a volume of NS injection equal to the volume of albumin (human) to be added to the IV bag (for 100 mL infusion use 2 mL of 5% albumin of 0.4 mL or 25% albumin, for 250 mL infusion use 5 mL of 5% albumin or 1 mL of 25% albumin); 2) add the appropriate volume of albumin to the IV bag and gently rotate; 3) add the albumin to IV bag and gently rotate to mix; 4) withdraw and discard a volume of the 0.1% albumin in NS injection from the IV bag equal to the volume of laronidase concentrate to be added; 5) slowly withdraw the required amount of laronidase from vials (avoid excessive agitation), then slowly add laronidase to the IV solution. Use immediately.  

ADMINISTER: IV Infusion: Infuse initially at 10 mcg/kg/h; may increase q15min during first h, as tolerated, to a max rate of 200 mcg/kg/hr. Maintain max for remainder of the infusion (2–3 h).  

INCOMPATIBILITIES Solution/additive: No compatibility data available. Do not recommend mixing or infusing with other drugs.

  • Store at 2°–8° C (36°–46° F). Do not freeze or shake. Discard any unused drug.

Adverse Effects (≥1%)

Body as a Whole: Infusion reactions (flushing, fever, headache, rash), injection site pain, hypersensitivity reactions. CNS: Hyperreflexia, paresthesias. CV: Chest pain, hypotension, edema. Hematologic: Thrombocytopenia. Respiratory: Upper respiratory tract infection. Skin: Rash.

Pharmacokinetics

Half-Life: 1.5–3.6 h.

Nursing Implications

Assessment & Drug Effects

  • Monitor for infusion-related reactions. Slow or stop infusion and notify physician for any of the following: cough, bronchospasm, dyspnea, urticaria, angioedema, pruritus, or other signs of hypersensitivity.
  • Lab tests: Periodic platelet count.

Patient & Family Education

  • Report promptly difficulty breathing, rash, or itching.

Common adverse effects in italic, life-threatening effects underlined; generic names in bold; classifications in SMALL CAPS; Canadian drug name; Prototype drug

(26)
This site is intended for general information only. The information provided on this site does not constitute medical advice and should not be relied upon. You should not act or refrain from acting on any legal or medical matter based on the content of this site.
© 2006-2025 medpill.info Last Updated On: 05/09/2025 (0.01)
×
Wait 20 seconds...!!!